INTRODUCTION {#s1}
============

Renal cell carcinoma (RCC) is the most frequent type of kidney neoplasm in adults. RCC presents as metastatic a diagnosis in almost 30% of patients and approximately 20% metastasizes after radical or partial nephrectomy \[[@R1]\] \[[@R2]\]. Although the prognosis of RCC patients has been dramatically increased by the introduction of anti-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs), anti-VEGF antibodies and mTOR inhibitors, the rate of patients who achieve complete remissions (CRs) is still poor \[[@R3]\]. The integration of these therapies with locoregional approaches is often proposed as a valid therapeutic option and should be evaluated case-by-case in order to optimize the outcome of RCC patients.

In 2012, Dr Albiges and her group described the results of a multicenter retrospective analysis including 64 patients who achieved CR during treatment with sunitinib or sorafenib administered alone or with local approaches. In this study, 53 patients (83%) stopped treatment after CR; of them, 29 patients (17 who had obtained CR with TKIs alone and 12 with additional local treatments) were still in CR at time of analysis \[[@R4]\].

Based on these results, several open questions still remain on: how can we early recognize patients who will achieve CR with targeted agents? What factors associate with the risk of recurrence after CR? Should we continue treating patients with targeted agents after CR? The answers to these questions will direct personalized strategies for mRCC patients and reduce the risk of recurrence after CR.

This multicenter retrospective analysis investigated prognostic factors and risk of recurrence in mRCC patients in CR after first-line targeted agents alone or in association with locoregional therapy. Secondary goal was to evaluate the risk of recurrence and conditional survival related to drug interruption vs continuation after CR.

RESULTS {#s2}
=======

Overall study population {#s2_1}
------------------------

Sixty three patients with CRs were enrolled in this analysis. The median follow-up time was 20.2 months (IQR 8.5-33.5). Forty-six of them were males (73%). Median age was 58 years (range 49--65 years). Tumor histology was predominantly clear cell (87%); 25 patients (40%) were metastatic at diagnosis. Lung (43%) and mediastinal and/or abdominal lymph nodes (30%) were the most frequent metastatic sites; 30 patients (48%) had more than one site of metastasis. Prognostic categories using MSKCC criteria were good in 40 pts (63%), intermediate in 23 patients (37%), whilst no patients had poor risk features. One hundred and seventy-nine patients were used as a control group. Complete patient demographics are shown in Table [1](#T1){ref-type="table"}.

###### Clinico-pathological characteristics of the overall population

  N (%)                                                 CR 63 patients   Non-CR 179 patients   *p-value*
  ----------------------------------------------------- ---------------- --------------------- --------------
  **Gender**                                                                                   0.265
  Male                                                  46 (73)          117 (65)              
  Female                                                17 (27)          62 (35)               
  **Median age (IQR)**                                  58 (49-65)       66 (57-87)            **\<0.001**
  **Karnofsky Performance Status at I line**                                                   **\<0.001**
  ≥90                                                   56 (89)          30 (17)               
  \<90                                                  7 (11)           149 (83)              
  **T Stage**                                                                                  0.073
  T1                                                    15 (24)          25 (14)               
  T2                                                    12 (19)          35 (19)               
  T3                                                    32 (51)          87 (49)               
  T4                                                    4 (6)            32 (18)               
  **Fuhrman grade**                                                                            0.067
  G1                                                    9 (14)           25(14)                
  G2                                                    27 (43)          46 (25)               
  G3                                                    21(33)           87 (49)               
  G4                                                    6 (10)           21 (12)               
  **Metastasis at RCC diagnosis**                                                              0.810
  M0                                                    38 (60)          111 (62)              
  M1                                                    25 (40)          68 (38)               
  **Histology**                                                                                0.643
  Clear cell RCC                                        55 (87)          152 (85)              
  Non-clear cell RCC                                    8 (13)           27 (15)               
  **Sarcomatoid aspects**                                                                      0.080
  No                                                    60 (95)          151 (84)              
  Yes                                                   3 (5)            28 (16)               
  **Previous nephrectomy**                                                                     **0.002**
  Yes                                                   55 (87)          120 (67)              
  No                                                    8 (13)           59 (33)               
  **Metastatic sites at start of first line therapy**                                          **0.002**
  Bone                                                  9 (14)           66 (37)               **\< 0.001**
  Lymph-nodes                                           19 (30)          91 (51)               **0.004**
  Lung                                                  27 (43)          122 (68)              **\<0.001**
  Liver                                                 8 (13)           51 (28)               **0.012**
  Pancreas                                              7 (11)           7 (4)                 0.035
  Adrenal glands                                        9 (14)           19 (11)               0.433
  Contralateral kidney                                  10 (16)          1 (1)                 **\<0.001**
  Brain                                                 8 (13)           24 (13)               0.886
  **N metastatic sites**                                                                       **\<0.001**
  1                                                     33 (52)          42 (24)               
  \>=2                                                  30 (48)          137 (76)              
  **MSKCC**                                                                                    
  Good risk                                             40 (63)          27 (15)               **\<0.001**
  Intermediate risk                                     23 (37)          140 (78)              **0.050**
  Poor risk                                             0                12 (7)                ---

CR = Complete remission; IFN-α = Interferon-α; MSKCC = Memorial Sloan Kettering Cancer Center; RCC= renal cell carcinoma

Comparing CR vs non-CR patients, age (Kruskal-Wallis *p*\<0.001) and Karnofsky Performance Status (Kruskal-Wallis *p*\<0.001) resulted significantly different between the two groups. No differences were found according to gender (*p*=0.260), tumor histology (*p*=0.643) and sarcomatoid differentiation (*p*=0.08). The absolute number of metastatic sites at start of first-line therapy was significantly higher in non-CR patients (*p*\<0.001), as well as the number of patients with good (*p*\<0.001) or intermediate (*p*=0.050) MSKCC criteria.

Finally, a significant difference in the proportion of metastatic sites were observed for bone, mediastinal and/or abdominal lymph nodes, lung and liver, which were more present in non-CR patients, whilst metastases to contralateral kidney were more frequent in patients with CR (Table [1](#T1){ref-type="table"}).

CR patients: locoregional approaches, drug interruptions and risk of recurrence {#s2_2}
-------------------------------------------------------------------------------

Fifty-one patients (81%) were treated with sunitinib, 9 with pazopanib (14%), 3 with bevacizumab and IFN-α (5%). Among them, dose reductions were performed in 28 patients (44%).

In 23 patients (37%), CR was obtained by TKI therapy alone, while 40 patients (63%) underwent additional loco-regional treatments, including surgery (88%), radiotherapy (8%) or both (4%). CR of brain metastases was obtained by radiotherapy and TKI therapy. After achieving CR, first-line TKI therapy was interrupted in 51 patients (81%) and continued in 12 patients (19%). Thirty-one patients (49%) recurred after CR. Of them, 27 had interrupted TKI therapy at CR (27/51, 53%) and 4 continued treatment after achieving CR (4/12, 33%). At recurrence, 15 of the 27 patients who had stopped TKI therapy was re-treated with the same TKI (56%), while the other 12 patients were treated with the another TKI (26%) or everolimus (5%). Four of the 15 patients who restarted therapy with the same agent do progressed during treatment, while only 1 patient progressed among the 12 patients who changed therapy. Complete detailed CR and recurrence characteristics are presented in Table [2](#T2){ref-type="table"}.

###### Locoregional approaches, drug interruptions and risk of recurrence

                                                 N (%)
  ---------------------------------------------- ---------
  **First-line therapy**                         
  Pazopanib                                      9 (15)
  Sunitinib                                      51 (81)
  Bevacizumab + IFN-α                            3 (3)
  **Response to first-line TKI**                 
  CR without additional treatment                23 (37)
  Additional loco-regional treatment             40 (63)
  **Type of locoregional treatment**             
  Metastasectomy                                 35 (88)
  Radiotherapy                                   3 (8)
  Combination therapy (surgery + radiotherapy)   2 (4)
  **Recurrence after CR**                        
  Yes                                            31 (49)
  No                                             32 (51)
  **Suspension of TKI after CR**                 
  Yes                                            51 (81)
  No                                             12 (19)
  **Therapy at recurrence after CR**             
  Same TKI used as first-line                    15 (56)
  Different TKI                                  7 (26)
  Everolimus                                     5 (19)

Among the 31 patients who recurred after CR, 14 (45%) relapsed in the same metastatic sites in which they had achieved CR, whilst 17 (55%) recurred in different sites. Furthermore, we analyzed the recurrence rate according to the site of metastases at the start of first- line therapy. We showed that the rate of recurrence was higher in patients with brain (88%), pancreatic (71%) and liver metastasis (63%) (Figure [1](#F1){ref-type="fig"}). In addition, the rate of recurrence was lower in patients with only one site of metastasis compared to ≥ 2 sites (41% vs 52%), while was comparable in good risk vs intermediate risk patients (48% vs 48%). Notably, the rate of recurrence was lower in patients who achieved CR with TKIs and locoregional interventions compared to patients treated with only TKIs (40% vs 61%).

![Risk of recurrence by metastatic site](oncotarget-07-33381-g001){#F1}

Outcome analyses: disease-free survival and overall survival {#s2_3}
------------------------------------------------------------

In patients with CR, median DFS was 28.2 months (95% CI 16.5--43.1). We further analyzed the median DFS based on the presence or absence of different metastatic sites. Patients with CR of brain metastases had significant shorter DFS compared to patients with CR of other metastatic sites (5.3 vs 32.4 months, *p*=0.002) (Figure [2](#F2){ref-type="fig"}). Otherwise, a significant difference was not found for lung (32.4 vs 28.2 months, *p*=0.534), liver (7.3 vs 32.4 months, *p*=0.073), adrenal gland (42.1 vs 25.1 months, *p*=0.184), bone (42.1 vs 25.1 months, *p*=0.093), pancreatic (5.6 vs 29.2 months, *p*=0.058), mediastinal and/or abdominal lymph nodes (25.1 vs 28.2 months, *p*=0.304) and contralateral kidney (28.2 vs 29.9 months, *p*=0.809). By stratifying patients for the number of metastatic sites (1 vs ≥2) the median DFS was 32.4 vs 21.6 months (*p*=0.288). Similarly, no difference was found in terms of DFS between patients with good vs intermediate risk criteria (28.2 vs 29.9 months, *p*=0.879).

![Disease Free Survival (DFS) in patients with CR of brain metastases compared to other metastatic sites](oncotarget-07-33381-g002){#F2}

Patients who achieved CR with the addition of loco-regional interventions had a longer DFS compared to patients who received TKI alone (41.9 vs 16.5 months, *p*=0.039) (Figure [3A](#F3){ref-type="fig"}). Interestingly, patients who continued TKI therapy after CR had a longer DFS than those who interrupted TKI administration. The difference was not statistically significant due to the different number of patients in the two groups (42.1 vs 25.1 months, *p*=0.254) (Figure [3B](#F3){ref-type="fig"}). Patients who experienced dose reductions during first-line therapy had comparable DFS compared to patients who maintained the standard doses (32.4 vs 25.1 months, *p*=0.855).

![Disease free survival (DFS) in CR patients with or without locoregional approaches to TKI therapy **A.** and on TKI interruption/continuation after achieving CR **B.**](oncotarget-07-33381-g003){#F3}

Median OS from the start of first-line therapy and from CR were not reached due to the fact that only 4 patients (6%) were dead at time of this analysis.

Univariate and multivariate analyses for DFS {#s2_4}
--------------------------------------------

At univariate analysis, the presence of metastases to pancreas (*p*=0.058; HR=2.54, 95% CI: 0.94−6.88), brain (*p*=0.002; HR=3.74, 95% CI: 1.52−9.21) and liver (*p*=0.073; HR=2.41, 95% CI: 0.89−6.48) and high Fuhrman grade (*p*=0.027; HR=2.12, 95% CI 1.37-3.15) were significantly associated with poor DFS. The addition of locoregional treatment to achieve CR (*p*=0.048; HR=0.47, 95% CI: 0.23−0.98) and the presence of metastases to adrenal gland (*p*=0.183; HR=0.39, 95% CI: 0.09−1.65) or bone (*p*=0.106; HR=0.37, 95% CI: 0.11−1.24) were correlated with significantly longer DFS. None of the other clinical variables, such as age, T stage, MSKCC group, number of metastatic sites and TKI interruption at CR were significantly associated with the outcome of CR patients. At multivariate analysis, the presence of liver (*p*=0.002; HR=4.13, 95% CI: 1.65−10.34) or brain metastases (*p*=0.045; HR=2.81, 95% CI: 1.02−7.69) and high Furhman grade (*p*=0.040; HR=1.98, 95% CI 1.36-5.65) were independent predictors of worst DFS (Table [3](#T3){ref-type="table"}).

###### Univariate and Multivariate analyses of predictors of DFS in patients with CR

  Disease Free Survival           Univariate Cox regression   Multivariate Cox regression                       
  ------------------------------- --------------------------- ----------------------------- ------------------- -----------
  **Age**                                                                                                       
  (\<60 y vs\>60 y)               1.61 (0.77-3.34)            0.206                                             
  **Fuhrman grading**             2.12 (1.37-3.15)            **0.027**                     1.98 (1.36-5.65)    **0.040**
  **T stage at diagnosis**        0.61 (0.29-1.27)            0.187                         0.91 (0.40-2.91)    0.803
  **Metastatic at diagnosis**                                                                                   
  No vs Yes                       1.18 (0.56-2.48)            0.662                                             
  **N. of metastatic sites**                                                                                    
  1 site vs \>1 site              1.49 (0.71-3.10)            0.289                                             
  **MSKCC risk group**                                                                                          
  Low risk vs Intermediate risk   1.06 (0.50-2.24)            0.885                                             
  **Type of CR**                                                                                                
  Surgery+TKIs vs TKIs alone      0.47 (0.23-0.98)            **0.048**                     0.80 (0.34-1.87)    0.603
  **TKI interruption at CR**                                                                                    
  Yes vs No                       1.25 (0.54-2.94)            0.602                                             
  **Metastatic sites**                                                                                          
  Lung                            0.79 (0.38-1.65)            0.534                                             
  Pancreas                        2.54 (0.94-6.88)            **0.058**                     1.55 (0.43-5.53)    0.499
  Adrenal gland                   0.39 (0.09-1.65)            **0.183**                     0.50 (0.11-2.27)    0.371
  Bone                            0.37 (0.11-1.24)            **0.106**                     0.46 (0.14-1.58)    0.220
  Brain                           3.74 (1.52-9.21)            **0.002**                     4.13 (1.65-10.34)   **0.002**
  Liver                           2.41 (0.89-6.48)            **0.073**                     2.81 (1.02-7.69)    **0.045**
  Lymph nodes                     0.60 (0.23-1.59)            0.308                                             
  Controlateral kidney            1.13 (0.42-2.99)            0.813                                             

Significant values are reported in bold. DFS= disease free survival, CR= complete remission

Univariate and multivariate analyses were not performed for OS due to the small number of events.

Conditional disease-free survival and overall survival {#s2_5}
------------------------------------------------------

For the overall population of complete responders, DFS at 2 years was 56.5%. Considering the increasing timepoints investigated, the survival advantage was +1.3 (2%) at 3 months, +5.9 (10%) at 6 and 9 months, +8.1 (14%) at 12 months. Stratifying by treatment received, 2y survival probability was 41.1% in patients treated with TKIs alone and 65.7% for patients treated with TKIs plus locoregional treatments. In the first group of patients, no survival advantages were seen after time, as shown by the data on cDFS presented in Figure [4](#F4){ref-type="fig"}, while for patients undergoing associated locoregional treatments a gain in survival rates of 3.9 (6%), 17.2 (26%), 18.7 (28%) and 23.2% (35%), respectively at 3, 6, 9, 12 months survival time was observed.

![Conditional Disease Free Survival (cDFS) in the overall CR population **A.** and stratified by drug interruption/continuation after CR. **B.** or treatment received (TKI versus TKI plus locoregional treatment) **C.**](oncotarget-07-33381-g004){#F4}

The effect of treatment suspension was also investigated under a cDFS fashion. Even though a 2 years cDFS reduction with time was observed, treatment prosecution, compared to suspension, was associated to a better cDFS at all investigated timepoints.

DISCUSSION {#s3}
==========

In this study, we first investigated the factors associated with the risk of recurrence in RCC patients with CR developed during first line therapy. We showed that the risk of recurrence after CR varies among the different metastatic sites that develop CR. Indeed, the presence of brain, bone or pancreatic metastases, even if obtained by TKIs alone or with local treatments, was associated with the highest risk of recurrence in patients with CR. In addition, the presence of brain or liver metastases was a predictor of worst DFS at multivariate analysis. The chance of CR seems to be influenced more by the site of metastasis than by the number of metastatic sites. In addition, our data showed that TKI interruption at CR was not a predictor of DFS at univariate and multivariate analysis, in accordance with the recent results from the registry-based analysis led by Buchler et al \[[@R11]\]. Taken together, these data support a personalized follow-up for mRCC patients based on the metastatic sites in CR.

In our study, 51 patients stopped therapy once in CR. Differently from the study led by Albiges et al. \[[@R4]\], the rate of patients who were still in CR after stopping therapy was lower in our study (47% vs 61%). This may be partially explained by the differences between the two study populations (i.e. not all of our CR patients underwent previous nephrectomy and no poor risk patients were included in our analysis).

In our study, patients that continued treatment after CR recorded 17 months of additional DFS. The small number of patients in both studies does not allow to definitively assess whether drug interruption can be safe and effective. Nevertheless our findings should be taken into consideration when dealing with CR mRCC patients. A significant advantage in terms of DFS was observed in patients treated with a multimodal approach compared to patients treated with TKI alone. Considering the low rate of recurrence and longer disease free interval in the group of patient treated with TKI and local therapy, multimodal treatment could be a valid approach to overcome tumor heterogeneity usually involved in TKI resistance.

Interestingly, dose reductions during TKI therapy were reported in 44% of CR patients and did not correlate with a higher rate of recurrence after CR. These findings should be considered to evaluate the choice of more tolerable strategies (i.e. reduced doses, alternative schedules) in patients in CR with TKIs. In addition, the potential of emerging immunotherapies, such as Immunocheckpoints inhibitors, as a maintenance therapy after achieving CR should be investigated in these patients. Indeed, Immunocheckpoints inhibitors can induce T cell--mediated memory response that is unattainable with TKI therapy, thus suggesting that the combination of these two different approaches may potentially increase the rate of patients without disease recurrence after obtaining CR with TKI therapy.

The early identification of patients who will develop CR or rapidly progress during first-line therapy represents a challenging issue in mRCC management. Clinicopathological data provide essential information in guiding treatment decisions, even if validated predictive biological factors associated with the response to targeted agents are still lacking. When comparing non-CR patients, we found that patients with CR were younger, presented a better Karnofsky Performance Status and a different metastatic distribution at the start of first-line therapy. These data suggest the employment of local approaches to achieve CR and emphasize the necessity for a multidisciplinary management of these patients.

However, there are several limitations to this study. First, its retrospective design, which may incur bias in data selection and analysis. Second, the lack of a central radiologist review of the CRs, which were separately evaluated and confirmed by the oncologists and the radiologists in each center. Furthermore, data on patient quality of life (QoL) would be an important integration for the results of our analysis. In addition, the study population was quite heterogeneous due to the presence of patients who had obtained a CR with or without locoregional therapies.

Despite these limitations, the present study shows that CR can be obtained by TKI therapy, either alone or in combination with local approaches. Drug continuation after CR should be carefully considered in RCC patients, even if perspective studies are dramatically needed to identify and validate predictive factors associated with the risk of recurrence after CR in this population.

PATIENTS AND METHODS {#s4}
====================

Study population {#s4_1}
----------------

This was a retrospective, observational multicenter study including patients consecutively treated for metastatic RCC from March 2006 to May 2014 (i.e. not on clinical trials or experimental protocols) and presenting with CR (absence of clinically and/or radiologically identifiable signs of the disease) on first-line therapy, administered alone or in combination with local treatments (i.e. metastasectomy, radiotherapy, radiofrequency ablation and stereotaxis) in accordance with their treating physician\'s practice. Baseline characteristics were obtained from patients\' clinical charts at admission from 13 Italian centers. Patients were collected consecutively to avoid selection bias and were excluded from the analysis if they had missing information about first-line therapy, sites of metastasis at the start of therapy, locoregional therapies, time to CR and recurrence. Patient follow-up was updated to May 2015.

Radiological CR was defined either with total body contrast-enhanced CT and/or MRI. Memorial Sloan Kettering Cancer Center (MSKCC) prognostic criteria \[[@R5]\], number and location of metastatic sites, type of CR (obtained by targeted therapy alone or by the addition of loco-regional approaches), drug interruption after complete response were considered as potentially relevant variables for differentiating the groups and for the purposes of outcome prediction.

CR patients were matched with a group of consecutive patients with non-CRs (partial responses, stable disease or progressive disease) to first-line therapy for metastatic RCC treated in the same period at the Campus Biomedico (Rome) and the AOU Ospedali Riuniti (Ancona).

Statistical analysis {#s4_2}
--------------------

Overall Survival (OS) was defined as the time from CR after first-line treatment to death, irrespective of cause. Disease-Free Survival (DFS) was defined as the time from CR to disease recurrence. OS and DFS were evaluated via the Kaplan-Meier method and Mantel-Haenszel log-rank test was employed to compare survival among groups. We considered distribution of clinical variables within each of the two groups of patients (CR vs non-CRs). Homogeneity of the two groups relating to variables distributions was tested by means of chi-squared test for difference in proportions.

Variable tendency measures were reported as mean (95% CI) or median (IQR) according to their distribution. Uniform distribution of categorical variables between the two groups compared was evaluated by means of chi-squared test. Levels of continuous variables between the two groups were compared by means of Kruskal-Wallis test.

Median OS and DFS were estimated by means of Kaplan-Meier product-limit method, while the Mantel-Haenszel log-rank test was used for statistical inference in the formal comparison between groups. A Cox-regression model was applied to the data with a univariate and multivariate approach. The assumption of proportionality of hazards was assessed using the Therneau and Grambsch test of the Schönefeld residuals \[[@R6]\]. Variables not fitting a univariate regression analysis were excluded for the multivariate model. No-multicollinearity of the grouped co-variates was also checked. Significance level in the univariate model for inclusion in the multivariate final model was more liberally set at a 0.2 level, according to Hosmer *et al*. \[[@R7]\]. All other significance levels were set at a 0.05 value.

Conditional DFS (cDFS) is the conditional probability for a patient to survive without experiencing recurrence for an additional number of years. Kaplan-Meier lifetables were employed to estimate cumulative survival at six different timepoints (3, 6, 9, 12 months from diagnosis of CR) and further at 24 months + each of the timepoints. Two-years cDFS relative to each timepoint was then obtained by dividing the survival rate at each of the 24 + timepoints months by the survival rate at the baseline timepoints. In other words, cDFS (2y\|timepoint)=S(timepoint+24)/S(timepoint) according to previous studies \[[@R8]\] \[[@R9]\] \[[@R10]\]. Comparison of changes in cDFS was further performed after stratification according to the most clinically relevant variables at univariate analysis.

All calculations were conducted by means the R Software v. 3.1.2 (The R Company- Vienna- Austria).
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